PSG
DRNA

Planning Solutions Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Planning Solutions Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$369K Buy
+23,442
New +$319K 0.19% 92

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Planning Solutions Group's DRNA Position: Q2 2019 in Review

Planning Solutions Group opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2019: 23,442 shares worth $369K. The stake represents 0.19% of the portfolio and ranks #92 among its holdings.

98 funds tracked by Wall St. Rank hold DRNA as of Q2 2019.

  • Planning Solutions Group held 23,442 shares of Dicerna Pharmaceuticals, Inc. worth $369K as of Q2 2019.
  • Dicerna Pharmaceuticals, Inc. was a new Planning Solutions Group position in Q2 2019.
  • Dicerna Pharmaceuticals, Inc. made up 0.19% of Planning Solutions Group's portfolio in Q2 2019, its #92 holding.
  • 98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2019.

Based on Planning Solutions Group's 13F filing for Q2 2019, filed 15 Aug 2019.